Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target
How effective is Summit Therapeutics’ lung cancer immunotherapy? Why are obesity drugmakers turning back to a two-decade-old idea? And how long will Elaine last as a new (official) co-host?
We talk about all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We discuss the next big trend in obesity drug development — treatments that target the amylin hormone. Companies argue that these types of drugs could lead to less nausea and muscle loss, and the first big readout is coming later this year.
